Date clarification: Rollins is scheduled to report after the market closes today, Wednesday, July 22, 2026, not tomorrow. The earnings call is scheduled for Thursday, July 23 at 8:30 a.m. ET.
Rollins enters 2Q26 with the core setup investors generally want for a pest-control compounder: a seasonally favorable quarter, management’s maintained 7%–8% organic-growth outlook, pricing running at 3%–4%, a healthy M&A contribution, and an operational backdrop that improved materially exiting 1Q.
The central question is no longer simply whether revenue grows. It is whether Rollins can convert seasonally stronger volumes into a clear step-up in margins and earnings growth after 1Q profitability was held back by elevated insurance claims, lower fleet gains, and deliberate front-loaded sales, marketing, and staffing investment.
The share price already reflects a more cautious setup: ROL closed at $43.87 on July 21, down roughly 23% from its April 23 closing high of $56.99. That reset may lower expectations, but the market will likely still demand evidence that the company’s growth investments, retention initiatives, and pricing are producing operating leverage.
Management reiterated its full-year outlook for 7%–8% organic growth and 2%–3% M&A-driven growth after 1Q. The key support was a strong March exit rate: total growth was about 12% and organic growth exceeded 8%, versus 6.6% organic growth for the full quarter after weather disrupted January.
For 2Q, investors should focus on:
Why it matters: 2Q is a major seasonal earnings period for Rollins. In 2Q25, the company delivered 12.1% total revenue growth and 7.3% organic growth. A result materially below that organic level—especially without a clear weather explanation—would likely raise questions about residential demand, lead flow, or execution.
Rollins’ 1Q segment organic-growth performance showed a meaningful mix difference:
| 1Q26 organic growth | Takeaway |
|---|---|
| Residential: 4.2% | The softest business, partly reflecting early-quarter weather |
| Commercial: 7.7% | Supported by investments in dedicated commercial sales resources |
| Termite & ancillary: 9.8% | Strongest category and an important indicator of cross-sell and consumer willingness to buy larger-ticket services |
The most constructive 2Q outcome would be:
The Romex acquisition, completed on April 1 for $90 million plus up to $10 million of contingent consideration, will also support reported growth in 2Q. Investors should distinguish carefully between acquired revenue and underlying organic momentum.
Rollins’ 1Q margin profile was the primary blemish:
| Metric | 1Q26 | YoY change |
|---|---|---|
| Gross margin | 50.8% | -60 bps |
| Adjusted operating margin | 16.9% | -100 bps |
| Adjusted EBITDA margin | 19.8% | -110 bps |
| Adjusted EBITDA incremental margin | 9.1% | Below the company’s longer-term potential |
Management identified several temporary or timing-related pressures:
Management was explicit that 1Q is typically the seasonal margin low point and expected improvement through 2Q and 3Q. Accordingly, this quarter should provide the first meaningful test of that assertion.
2Q25 sets a solid comparison base:
| 2Q25 result | Reported outcome |
|---|---|
| Revenue growth | 12.1% |
| Organic growth | 7.3% |
| Gross margin | 53.8% |
| Adjusted EBITDA margin | 23.1% |
| Adjusted EPS | $0.30 |
| Free cash flow growth | +23% |
The comparison is not easy: 2Q25 already included healthy organic growth, a strong seasonal gross margin, and robust cash conversion. Still, the 2026 setup has several offsets: Romex contributes to inorganic growth, pricing remains constructive, commercial investment should be maturing, and Rollins has entered the season with a fully staffed service and sales organization.
Cash conversion should improve from the distorted 1Q result. Free cash flow was $111 million in 1Q, down year over year, but management attributed the decline largely to:
Management said those timing effects should moderate during the year, with a more meaningful benefit by 4Q. Thus, a better cash-flow trend in 2Q would support confidence in the earnings quality and full-year cash-conversion outlook.
The balance sheet remains flexible despite acquisition activity:
This leaves Rollins able to continue its disciplined M&A strategy while maintaining its dividend and investing in organic growth.
A favorable market reaction would likely require some combination of:
The principal downside risks are:
The 2Q26 report is principally a margin-validation event. Rollins’ long-term growth profile remains attractive: recurring pest-control revenue, pricing power, commercial expansion, ancillary-service cross-selling, strong cash conversion, and a balance sheet capable of supporting bolt-on acquisitions.
However, after 1Q’s margin compression, investors need proof that the company can translate its healthy demand backdrop into stronger flow-through. If organic growth remains around the 7%–8% target and margins improve as management indicated, the report should reinforce the argument that 1Q was a seasonal and timing-driven trough rather than a deterioration in the earnings algorithm.